A Phase 1B Study of Intralesional Injection of RP1 in Patients With Resectable Cutaneous SCC
Latest Information Update: 28 Mar 2024
At a glance
- Drugs Vusolimogene oderparepvec (Primary)
- Indications Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Mar 2024 Status changed from not yet recruiting to recruiting.
- 18 May 2023 New trial record